John Litten, Patient & Advocate

home / authors / john-litten-patient-advocate

Articles

Advances in Prostate Cancer

Advances in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Future Use of PARP Inhibition in Prostate Cancer

Future Use of PARP Inhibition in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Advice to Patients Facing mCRPC

Advice to Patients Facing mCRPC

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
PARP Inhibitors in Recurrent mCRPC

PARP Inhibitors in Recurrent mCRPC

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Treatment Options Available for mCRPC

Treatment Options Available for mCRPC

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
John Litten: Participating on a PARP Clinical Trial for mCRPC

John Litten: Participating on a PARP Clinical Trial for mCRPC

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Talking About Gene Testing in Prostate Cancer

Talking About Gene Testing in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Testing for Mutations in Prostate Cancer

Testing for Mutations in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Prostate Cancer: Learning About Treatment Options

Prostate Cancer: Learning About Treatment Options

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Receiving a Prostate Cancer Diagnosis

Receiving a Prostate Cancer Diagnosis

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Metastatic Castration-Resistant Prostate Cancer Overview

Metastatic Castration-Resistant Prostate Cancer Overview

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
The Future of PARP Inhibitors in Prostate Cancer

The Future of PARP Inhibitors in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Patient’s Role in Decision-Making for Prostate Cancer

Patient’s Role in Decision-Making for Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Quality of Life With Prostate Cancer

Quality of Life With Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
FDA-Approved PARP Inhibitors for Prostate Cancer

FDA-Approved PARP Inhibitors for Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Impact of BRCA Mutations in Prostate Cancer

Impact of BRCA Mutations in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Genetic Counseling for Prostate Cancer

Genetic Counseling for Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Diagnosis of Prostate Cancer

Diagnosis of Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020